跳至主要内容
临床试验/EUCTR2005-000192-17-GB
EUCTR2005-000192-17-GB进行中(未招募)1 期

Gemcitabine and Oxaliplatin in the treatment of locally advanced or metastatic transitional cell carcinoma of the urinary tract in patients with impaired renal function and patients who have progressed on a cisplatin-based regimen - GO-80 protocol in TCC urinary tract

Barts & The London NHS Trust0 个研究点目标入组 28 人开始时间: 2005年4月25日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
28

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Locally-invasive or metastatic transitional cell carcinoma of the urinary tract – from the renal pelvis to the bladder.
  • 2. Males and females >16 years of age.
  • 3. Life expectancy >12 weeks.
  • 4. ECOG performance status 0–3 (see appendix).
  • 5. Adequate bone marrow function (to be determined within 14 days of randomisation):
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Previous chemotherapy with gemcitabine or oxaliplatin
  • 2. Untreated patients with a creatinine clearance > 60 ml/min
  • 3. Concurrent participation in any other investigational drug study.
  • 4. Unable to give written informed consent

研究者

相似试验